What is SPRAVATO®?
Spravato (esketamine) is a breakthrough treatment used to treat major depressive disorder (MDD) and treatment-resistant depression (TRD) in adults. Spravato is a unique medication with a different mechanism of action from traditional antidepressant medications such as selective serotonin reuptake inhibitors also known as SSRIs. In the context of depression, it is believed that Spravato can help to increase the activity of certain neurotransmitters, such as glutamate, which may alleviate symptoms of depression.
Spravato is administered through a nasal spray, which is used in conjunction with an antidepressant medication to treat depression in adults who have not responded to other treatments. Spravato is FDA approved for use in TRD, which is a more severe form of depression that does not respond to multiple medications.
It is important to note that Spravato can have significant side effects, including sedation, dissociation, and an increased risk of abuse and dependence. As such, it is only available through a restricted distribution program and must be administered in a healthcare setting under the supervision of a healthcare provider.
If you are experiencing symptoms of depression or have taken two or more antidepressants and still experience symptoms of depression, you can ask your healthcare provider at MindWell Urgent Care if Spravato is right for you. MindWell Urgent Care offers same-day mental health appointments through telemedicine and in-person visits.
- Please see additional Important Safety Information in this brochure.
- Click here for full Prescribing Information, including Boxed WARNINGS.
- Click here for the Medication Guide for SPRAVATO®, and discuss any questions you may
have with your healthcare provider.
Spravato is covered by most major insurance payers.